TY - JOUR

T1 - Manufacturing and characterization of autologous CD19-specific CAR T-cell products for patients with autoimmune rheumatic diseases

AU - Беловежец, Татьяна Николаевна

AU - Омельченко, Виталий Олегович

AU - Рыбакова, Анна Дмитриевна

AU - Королев, Максим Александрович

AU - Горчаков, Андрей Александрович

AU - Кулемзин, Сергей Викторович

N1 - Manufacturing and characterization of autologous CD19-specific CAR T-cell products for patients with autoimmune rheumatic diseases / T. N. Belovezhets, V. O. Omelchenko, A. D. Rybakova [et al.] // Cellular Therapy and Transplantation. – 2025. – Vol. 14. - No. 3. – P. 59-65. – DOI 10.18620/ctt-1866-8836-2025-14-3-59-65. – EDN KFIOGW. The work was performed by agreement No. 075-15-2025-580 from June 25, 2025 between the Ministry of Science and Higher Education of the Russian Federation, and the Institute of Cytology and Genetics SB RAS.

PY - 2025/9/30

Y1 - 2025/9/30

N2 - CAR T-cell therapy of patients with autoimmune diseases is an emerging approach to selectively deplete B cells, thereby reducing the need for lifelong use of immunosuppressive drugs. In theory, all autoimmune diseases in which B cells are known to be key pathogenic effectors could respond well to B-cell targeting CAR T-cell therapy. In practice, however, successful manufacturing of autologous CAR T-cell products critically depends on the quality of the patient’s T cells as a starting material, and may require early discontinuation of immunosuppressive therapy prior to apheresis. Additionally, many autoimmune diseases are characterized by abnormal levels of proinflammatory cytokines, which shift T-cell subpopulations toward less functional phenotypes. In this study, we demonstrate the feasibility of generating CD19-specific CAR T-cell products from several patients with different autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis, and systemic sclerosis. For five out of six patients, CAR T-cell products displaying pronounced cytotoxicity against B-cell targets were successfully manufactured and compared side by side with CAR T-cell products derived from healthy donors.

AB - CAR T-cell therapy of patients with autoimmune diseases is an emerging approach to selectively deplete B cells, thereby reducing the need for lifelong use of immunosuppressive drugs. In theory, all autoimmune diseases in which B cells are known to be key pathogenic effectors could respond well to B-cell targeting CAR T-cell therapy. In practice, however, successful manufacturing of autologous CAR T-cell products critically depends on the quality of the patient’s T cells as a starting material, and may require early discontinuation of immunosuppressive therapy prior to apheresis. Additionally, many autoimmune diseases are characterized by abnormal levels of proinflammatory cytokines, which shift T-cell subpopulations toward less functional phenotypes. In this study, we demonstrate the feasibility of generating CD19-specific CAR T-cell products from several patients with different autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis, and systemic sclerosis. For five out of six patients, CAR T-cell products displaying pronounced cytotoxicity against B-cell targets were successfully manufactured and compared side by side with CAR T-cell products derived from healthy donors.

KW - CAR T терапия

KW - CD19

KW - В-клетки

KW - аутоиммунные заболевания

KW - CAR T THERAPY

KW - B CELLS

KW - CD19

KW - AUTOIMMUNE DISEASES

UR - https://www.scopus.com/pages/publications/105024120397

UR - https://elibrary.ru/item.asp?id=83202444

UR - https://www.mendeley.com/catalogue/13b63426-1878-3b0a-8afd-dda4ada3db52/

U2 - 10.18620/ctt-1866-8836-2025-14-3-59-65

DO - 10.18620/ctt-1866-8836-2025-14-3-59-65

M3 - Article

VL - 14

SP - 59

EP - 65

JO - Cellular Therapy and Transplantation

JF - Cellular Therapy and Transplantation

SN - 1867-416X

IS - 3

M1 - 5

ER -